Compared to inhibitory effect of AZD3759 on the JAK/STAT pathway, that of osimertinib was relatively mild, which might be responsible for the uncompetitive anti-tumor properties observed in glioma cells and xenograft animal models. Here, SOAT1 is linked to neoplasm.